Atomera Inc. ATOM
Atomera's MST IP-licensing model is on the cusp of first commercial customer ramps; probability-weighted fab adoption scenarios support a $28 price target with moonshot upside to $146.
Thesis
Craig-Hallum maintains a BUY rating and $28 price target on Atomera (ATOM, $24.50) following a virtual non-deal roadshow with CEO Scott Bibaud and CFO Frank Laurencio. The note argues ATOM is making real progress moving customers through its commercialization funnel toward Phase 4 despite industry capacity constraints slowing R&D wafer runs. Qualification of the new 300mm epi tool is advancing, and ATOM is broadening its go-to-market by hiring a PR firm to directly target fabless semi makers after early traction with an unnamed RF fabless customer. The valuation rests on a probability-weighted scenario model — base case 7 fabs ($14), upside 15 fabs ($48), moonshot 50 fabs ($146) — using 2% royalty rate, $1,150 ASP/wafer, 60% fab utilization, and 95% gross margins, blended 75/20/5 to a $28 target.
SCQA
Atomera is a small-cap materials engineering company (mkt cap $551M) licensing its MST technology to semiconductor manufacturers under a royalty-based business model, currently pre-revenue with multiple customers in Phase 3 engagement.
Industry-wide fab capacity constraints are slowing the R&D wafer runs needed to qualify MST, elongating timelines, and ATOM has yet to convert any Phase 3 engagement into a paying production customer.
Maintain BUY: ATOM is qualifying its 300mm epi tool, hiring PR support to court fabless customers directly, and is positioned to push at least one customer to Phase 4 in the next few quarters.
Probability-weighted target of $28 (~14% upside); moonshot 50-fab scenario implies $146/share at 30x EPS, with 95% gross margins making the earnings model exceptionally leveraged.
The three reasons
- 1
ATOM nearing Phase 4 customer commercialization in next few quarters
- 2
Most leveraged earnings model analyst has seen — tiny revenue scales to huge EPS
- 3
Probability-weighted scenario yields $28 PT vs $24.50 current price
KPIs cited
Pattern membership
Composition what's on the 6 slides
Slide gallery ·
Notes
Sell-side BUY research note from Craig-Hallum (Richard Shannon / Sam Peterman), filed inside the White Diamond Research folder — almost certainly archived by White Diamond as opposition/context material, since White Diamond is a known short-seller of ATOM. This is NOT primary contrarian material; is_primary_material=False. Document is a 'view from the road' follow-up note (initial coverage was June 9, 2021), built around a probability-weighted scenario valuation: 75% base / 20% upside / 5% moonshot. No SCQA structure in the contrarian sense — standard sell-side template with Our Call / Investment Highlights / Stock Opportunity / Risks / model tables. Visual style is plain analyst-memo (Times Roman, two-column with stat sidebar, B&W tables) — visual_quality=2. campaign_phase set to 'unknown' since this is third-party analyst coverage, not part of an activist or short campaign authored by the folder owner.